RP-3 by Replimune for Gastrointestinal Tract Cancer: Likelihood of Approval

RP-3 is under clinical development by Replimune and currently in Phase I for Gastrointestinal Tract Cancer.

Chemo-Free Quadruplet Promising as Initial Treatment in DLBCL

Initial treatment with lenalidomide (Revlimid), tafasitamab (Monjuvi), rituximab, and acalabrutinib (Calquence) led to complete responses (CRs) in 64% of patients with newly diagnosed diffuse large

December 28, 2023

NIAID awards grants for 10 projects to improve diagnostic tools for syphilis

The National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID) has awarded grants for 10 projects to improve diagnostic tools for congenital

September 3, 2024

APONTIS PHARMA AG (von First Berlin Equity Research GmbH) – Biotech Investments

Original-Research: APONTIS PHARMA AG – from First Berlin Equity Research GmbH 16.08.2024 / 10:41 CET/CESTDissemination of a Research, transmitted by EQS News – a service

August 17, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.